Knopp Biosciences, a drug discovery company developing novel treatments for immunological and neurological diseases, announced that it entered the second year of the NIH-funded research to utilize its Kv7 platform to discover and develop non-opioid therapies for the treatment of chronic pain.
The project is funded by the NIH program called Helping to End Addiction Long-term (the NIH HEAL Initiative), which is an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. The grant funding of as much as $8 million is contingent upon the attainment of milestones over five years.
Knopp is advancing a portfolio of selective modulators of Kv7.2/7.3 voltage-gated potassium channels for the treatment of epileptic encephalopathy, neuropathic pain, hearing disorders and ALS.
Photo by Polina Tankilevitch from Pexels